Orgenesis announced that it has entered into an agreement with Columbia University, by which it will fund research to develop a cellular vaccination product platform, which it has licensed from Columbia University, for pancreatic, hepatic and cholangiocarcinoma cancers. Orgenesis will receive exclusive license on the technology developed at Columbia University under the research agreement. This patented dual-vaccine design utilizes whole cancer cells as a source of antigens and the patient’s dendritic cells and macrophages to present the cancer antigens to the immune system. It differs from similar approaches, which use dendritic cells pulsed with individual tumor-associated antigens or peptides. When individual tumor antigens are selected for targeting cancer cells it leaves a possibility that cancer cells will mutate and thus evade the immune system response. Conversely, targeting the entire repertoire of tumor cell antigens leaves little or no possibility for cancer cells to escape the immune system response.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.